Lexeo Therapeutics, Inc.
Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
About
CEO
Mr. R. Nolan Townsend
Employees
69
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
345 Park Avenue South, New York, NY 10010, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 13, 2024 | -0.68 | -0.89 | -0.21 | 30.88% |
| Aug 12, 2024 | -0.69 | -0.64 | 0.05 | -7.25% |
| May 9, 2024 | -0.77 | -0.77 | 0.00 | 0.00% |
| Mar 11, 2024 | -0.73 | -0.85 | -0.12 | 16.44% |
| Dec 11, 2023 | -2.60 | -12.36 | -9.76 | 375.38% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 6 |
| Average estimate | — | -0.80 | — | -3.01 |
| Low estimate | — | -0.93 | — | -3.84 |
| High estimate | — | -0.53 | — | -1.79 |
| Last year EPS | — | -0.77 | — | -2.75 |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
-3.250%
Current year
74.890%
Next year (Dec 2025)
2.440%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | — |
| Cost of revenue | — |
| Gross profit | — |
| Operating expense | |
| Research & development | 53.13M |
| Selling general and admin | 15.38M |
| Other operating expenses | — |
| Operating income | -68.51M |
| Non operating interest income | |
| Income | 2.87M |
| Expense | 205,000 |
| Other income expense | -543,000 |
| Pretax income | -66.39M |
| Tax provision | — |
| Net income | -66.39M |
| Basic EPS | -12.40 |
| Diluted EPS | -12.40 |
| Basic average shares | 5.35M |
| Diluted average shares | 5.35M |
| EBITDA | -63.82M |
| Net income from continuing op. | -66.39M |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 139.81M | 97.08M | 136.86M | 29.41M |
| Current assets | ||||
| Cash | — | — | — | 29.37M |
| Cash equivalents | — | — | — | — |
| Cash and cash equivalents | 121.47M | 77.34M | 135.86M | 29.37M |
| Other short term investments | — | — | — | — |
| Accounts receivable | — | — | — | — |
| Other receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Prepaid assets | 2.83M | 2.34M | 128,000 | — |
| Restricted cash | — | — | — | — |
| Assets held for sale | — | — | — | — |
| Hedging assets | — | — | — | — |
| Other current assets | 3,000 | 371,000 | 696,000 | 33,572 |
| Non current assets | ||||
| Properties | 11.72M | 13.06M | 187,000 | — |
| Land and improvements | — | — | — | — |
| Machinery furniture equipment | 676,000 | 620,000 | — | — |
| Construction in progress | — | — | — | — |
| Leases | 247,000 | 232,000 | — | — |
| Accumulated depreciation | -381,000 | -133,000 | -13,000 | — |
| Goodwill | — | — | — | — |
| Investment properties | — | — | — | — |
| Financial assets | — | — | — | — |
| Intangible assets | — | — | — | — |
| Investments and advances | — | — | — | — |
| Other non current assets | 3.25M | 3.25M | — | 2,500 |
| Total liabilities | 26.27M | 210.03M | 192.46M | 34.95M |
| Current liabilities | ||||
| Accounts payable | 3.79M | 2.68M | 3.06M | 44,319 |
| Accrued expenses | 7.70M | 6.18M | 2.85M | 250,098 |
| Short term debt | 2.61M | 2.83M | — | — |
| Deferred revenue | — | — | 46,000 | 140,384 |
| Tax payable | 157,000 | 506,000 | 528,000 | 38,304 |
| Pensions | 2.81M | 1.91M | 931,000 | — |
| Other current liabilities | 169,000 | 240,000 | 30,000 | 1,030 |
| Non current liabilities | ||||
| Long term debt | 9.03M | 10.65M | — | — |
| Provision for risks and charges | — | — | — | — |
| Deferred liabilities | — | — | — | — |
| Derivative product liabilities | — | — | — | — |
| Other non current liabilities | — | — | — | — |
| Shareholders equity | ||||
| Common stock | 3,000 | — | 2,000 | 1,604 |
| Retained earnings | -181.84M | -115.45M | -56.17M | -5.55M |
| Other shareholders equity | — | — | — | — |
| Total shareholders equity | 113.54M | -112.95M | -55.60M | -5.54M |
| Additional paid in capital | 295.37M | 2.49M | 565,000 | 9,794 |
| Treasury stock | — | — | — | — |
| Minority interest | — | — | — | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | -66.39M |
| Depreciation | 1.84M |
| Deferred Taxes | — |
| Stock-Based Compensation | 3.04M |
| Other Non-Cash Items | 530,000 |
| Accounts Receivable | — |
| Accounts Payable | -180,000 |
| Other Assets & Liabilities | -1.42M |
| Operating Cash Flow | -62.58M |
| Investing Activities | |
| Capital Expenditures | -115,000 |
| Net Intangibles | -50,000 |
| Net Acquisitions | — |
| Purchase of Investments | — |
| Sale of Investments | — |
| Investing Cash Flow | -115,000 |
| Financing Activities | |
| Long-Term Debt Issuance | 4.00M |
| Long-Term Debt Payments | -425,000 |
| Other Financing Charges | -86,000 |
| Financing Cash Flow | 103.74M |
| Other Cash Details | |
| End Cash Position | 124.72M |
| Income Tax Paid | — |
| Interest Paid | 176,000 |
| Free Cash Flow | -59.66M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | Sep 30, 2024 | 1,525,517 | 8.27M | 4.61% |
| Janus Henderson Global Life Sciences Fund | Sep 30, 2024 | 731,182 | 3.96M | 2.21% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 646,469 | 3.50M | 1.96% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 404,869 | 2.19M | 1.22% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 272,700 | 1.48M | 0.82% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 236,920 | 1.28M | 0.72% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 196,668 | 1.07M | 0.59% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 136,662 | 740,708 | 0.41% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 112,257 | 608,432 | 0.34% |
| Schwab Capital Trust-Small Cap Index Fund | Oct 31, 2024 | 56,174 | 304,463 | 0.17% |
Article
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P.
Jan 7, 2025
Article
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs.
Dec 19, 2024
Article
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025 Appointed Tolga Tanguler to Board of Directors, an accomplished biopharmaceutical executive with over 25 years of senior leadership experience Cash and cash equivalents of $157.0 million expected to provide operational runway into 2027 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today provided business updates across its portfolio of programs and reported third quarter 2024 financial results. “We have made significant progress over the last few months across all our clinical stage programs, including reaching alignment with the FDA on registrational endpoints to support an accelerated approval pathway for LX2006.
Nov 13, 2024
